[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100120042":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":34,"responsibleParty":46,"collaborators":33,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":33,"acronym":33,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":33,"enrollmentInfo":57,"targetDuration":33,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":33,"overallStatus":66,"whyStopped":67,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Allergan","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tazarotene Cream 0.1%","ACTIVE_COMPARATOR","1 pea-size amount, QD x 16 weeks",[13],"Drug: Tazarotene Cream 0.1%",{"label":15,"type":10,"description":11,"interventionNames":16},"Adapalene Gel 0.3%",[17],"Drug: Adapalene",[19,24],{"type":20,"name":9,"description":11,"armGroupLabels":21,"otherNames":22},"DRUG",[9],[23],"TAZORAC® Cream 0.1%",{"type":20,"name":25,"description":11,"armGroupLabels":26,"otherNames":27},"Adapalene",[15],[28],"Differin® Gel 0.3%",[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",null,[35],{"facility":33,"status":33,"city":36,"state":37,"zip":33,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":33},"Fremont","California","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-121.98857,37.54827,{"lat":44,"lon":43},{"type":47,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100120042","phase-4-safety-and-efficacy-of-tazarotene-cream-01-compared-with-adapalene-gel-03-in-the-treatment-of-moderate-to-severe-facial-acne-vulgaris-100120042",true,"NCT00829049","Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","Inclusion Criteria:\n\n* Facial acne vulgaris characterized by the following: 25-100 facial inflammatory lesions (papules plus pustules); and 40 or more non-inflammatory lesions (open\u002Fclosed comedones)); stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or less facial nodules and\u002For cysts (diameter of 1cm or greater).\n* Female subjects of childbearing potential must have a negative urine pregnancy test at baseline and practice reliable method of contraception throughout the study.\n\nExclusion Criteria:\n\n* Non-compliance with washout period\n* Skin disease\u002Fdisorder that might interfere with diagnosis or evaluation of acne vulgaris\n* Allergy or sensitivity to any component of the test medications\n* Cosmetic or surgical procedure complementary to the treatment of facial acne within 14 days of the baseline visit",false,"ALL","12 Years",{"count":58,"type":59},165,"ACTUAL","INTERVENTIONAL",[62],"PHASE4","Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris",[65],"Acne Vulgaris","TERMINATED","Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.","2012-08-20",{"date":70,"type":71},"2012-09-12","ESTIMATED",{"date":73,"type":33},"2007-10",{"date":75,"type":59},"2008-10",{"name":5,"class":6},1]